GlassScriptPhysician profile
Krunal Jethwa
NPI 1457607400
$1,140.87
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $832 · 2020: $157 · 2021: $68.13 · 2022: $83.81.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $274.13 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $160.79 | 2019 | |
| Astellas Pharma US INC | $96.86 | 2019-2020 | |
| Amgen INC. | $86.22 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $85.07 | 2019-2020 | |
| Pfizer INC. | $74.66 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $59.81 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $54.92 | 2019-2020 | |
| Lilly USA, LLC | $48.14 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $32.54 | 2022 | |
| Sanofi-Aventis U.S. LLC | $29.59 | 2019 | |
| Amarin Pharma, INC. | $28.53 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.70 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.83 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.36 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $14.58 | 2019 | |
| Glaxosmithkline, LLC. | $12.96 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $11.18 | 2020 | |
| Merck Sharp & Dohme LLC | $11.00 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krunal Jethwa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.